Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Non-Current Assets (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Non-Current Assets for 8 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 19.92% to $1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.8 million, a 124.99% increase, with the full-year FY2025 number at $1.2 million, changed N/A from a year prior.
  • Non-Current Assets was $1.1 million for Q4 2025 at Outlook Therapeutics, down from $1.2 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $1.3 million in Q4 2024 to a low of $1.1 million in Q4 2025.